Scinai Immunotherapeutics Ltd
F:2F50
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Scinai Immunotherapeutics Ltd.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Scinai Immunotherapeutics Does
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies.
- Headquarters
- Israel IL
- Employees
- 45
- IPO date
- Jun 7, 2007
Continue 2F50 Research
Decided on Scinai Immunotherapeutics? Get an email when 2F50 reaches the price you’d buy at. Free with an account.